Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 90Lung Neoplasms 34Meningeal Carcinomatosis 11Neoplasms 9Neoplasm Metastasis 7Adenocarcinoma of Lung 6Colorectal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Mesothelioma, Malignant 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Mesothelioma 3Carcinoma 3Advanced Solid Tumors 3Non Squamous Non Small Cell Lung Cancer 2Neoplasms by Site 2Neoplasms by Histologic Type 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Vaccinia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Carboplatin 4pertuzumab 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Paclitaxel 2Oxaliplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1talazoparib 1sarilumab 1relugolix 1regorafenib 1pexidartinib 1pembrolizumab 1patritumab 1olaparib 1niraparib 1nimotuzumab 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pathologic Complete Response × Pemetrexed × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡